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Abstract Glutamate-gated chloride (GluCl) channels from in-
vertebrates can be activated by ivermectin (IVM) to produce
electrical silencing in mammalian neurons. To improve this
GluCl/IVM strategy, we sought to mutate the Caenorhabditis
elegans GluCl channels so that they become insensitive to glu-
tamate but retain their sensitivity to IVM. Based on structure^
function studies of nicotinic acetylcholine receptor superfamily
members, we tested in oocytes 19 point mutants at 16 residues in
the L-subunit likely to be involved in the response to glutamate.
Y182F reduces the glutamate response by greater than six-fold,
with little change to IVM responses, when coexpressed with
wild-type (WT) GluCl K. For GluCl KL(Y182F), the EC50
and Hill coe⁄cient for glutamate are similar to those of WT,
indicating that the mutant decreases the e⁄cacy of glutamate,
but not the potency. Also, £uorescent proteins (enhanced green
£uorescent protein, enhanced yellow £uorescent protein, en-
hanced cyan £uorescent protein; XFP) were inserted into the
M3^M4 loop of the GluCl K, L and L(Y182F). We found no
signi¢cant functional di¡erence between these XFP-tagged re-
ceptors and WT receptors. The modi¢ed GluCl channel, without
glutamate sensitivity but with a £uorescent tag, may be more
useful in GluCl silencing strategies. < 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Several recent studies describe expression of exogenous ion
channels in order to change the electrical properties of neu-
rons [1^8]. Our laboratory has developed a procedure that
employs the glutamate-gated chloride (GluCl) channels from
Caenorhabditis elegans [9^11]. Because the anthelminthic iver-
mectin (IVM) activates these channels at concentrations too
low to a¡ect other mammalian ion channels, it is possible to
envision a procedure that selectively silences the target neu-
rons. The GluCl channels would be expressed in the target
neurons either by local injection of viral vectors or in trans-
genic animals under cell-speci¢c promoters.
The GluCl/IVM technique could be improved in two ways.
First, the GluCl channels should be rendered insensitive to
glutamate, which is present in CSF and released during syn-
aptic transmission. Second, the expression of the GluCl chan-
nels should be physically veri¢able by a technique that has
higher throughput than electrophysiology. Fluorescent pro-
teins are widely employed for such purposes; and the channels
could be fused to £uorescent proteins.
We chose the GluCl channels in part because they are mem-
bers of the nicotinic receptor superfamily, which has been
widely studied by mutagenesis [12]. Therefore several prece-
dents suggest ways to re-engineer the GluCl channels [13^15].
For the goal of eliminating glutamate responses while retain-
ing IVM responses, one considers the residues in the N-termi-
nal region known to bind agonists (Fig. 1) [16,17]. For the
goal of introducing £uorescent proteins, previous results sug-
gest that the intracellular loop between the M3 and M4 do-
mains is the appropriate region [18].
2. Materials and methods
2.1. Mutagenesis
Wild-type (WT) C. elegans GluCl K and GluCl L genes [11] cloned
into pBluescript II SKþ were a gift from Merck Research Laborato-
ries. In our present study [9], they were cloned into pcDNA 3.1
(ClonTech, Palo Alto, CA, USA) with KpnI and NotI. Site-directed
mutagenesis was performed on the GluCl L subunit using the Quik-
Change mutagenesis kit (Stratagene, La Jolla, CA, USA), and the
mutations were con¢rmed by sequencing.
2.2. Fluorescent protein-tagged constructs
Enhanced green £uorescent protein (EGFP), yellow £uorescent pro-
tein (EYFP), and cyan £uorescent protein (ECFP) were obtained
from ClonTech. The PCR primers 5P-TCCACCGGGCCGG-
CAAATGGTGAGCAAGGGC-3P and 5P-GTCGCGGCGCCGGC-
GCTTGTACAGCTCGTCCA-3P were used to PCR amplify EYFP
or EGFP, and the resultant PCR product was ligated into the Ngo-
MIV site of GluCl K, which positions the tag immediately after the
arginine at residue 408, the 49th out of 73 residues in the M3^M4
loop. The PCR primers 5P-CACCGGTCTTCGAAATGGTGAGCA-
AGGGC-3P and 5P-TCGCGGCCTTCGAACTTGTACAGCTCGTC-
C-3P were used to PCR amplify ECFP, and the resultant PCR product
was ligated into the Csp45I site of GluCl L, which positions the tag
immediately after the phenylalanine at residue 373, the 43rd out of 69
residues in the M3^M4 loop.
2.3. Expression of GluCl cRNAs
The cDNAs were linearized by NotI. All cRNAs were transcribed
in vitro using the T7 mMESSAGE mMACHINE kit (Ambion, Aus-
tin, TX, USA) as appropriate. RNAs were then quantitated by Ribo-
Green1 RNA Quantitation kit (Molecular Probes, Eugene, OR,
USA). Stages V^VI Xenopus laevis oocytes were harvested and in-
jected with 50 nl/oocyte of a mixture containing 25^375 pg per subunit
of cRNAs for WT, mutant and XFP constructs, in equimolar
amounts of K and L. The size of the XFP coding region is V0.7 kb
and that of the GluCl subunits is V1.4 kb, thus 1.5 times greater
mass of an XFP-tagged subunit cRNAs was injected compared with
WT subunits. After injection, oocytes were incubated at 18‡C in ND-
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96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2
and 5 mM HEPES, pH 7.5, osmolarity 230 mOsm) supplemented with
50 Wg/ml gentamicin, 2.5 mM pyruvate and 0.6 mM theophylline.
2.4. Electrophysiology
Recordings were carried out 24^36 h after injection. Membrane
potential was held at 360 mV in Ca2þ-free ND-96 with two electrodes
(¢lled with 3 M KCl, resistance 0.5^3 M6) using a GeneClamp 500
circuit and a Digidata 1200 digitizer from Axon Instruments (Union
City, CA, USA) interfaced with an IBM-compatible PC running
pCLAMP 8.0 software from Axon. Drugs were applied with a dead
time of 1 s. Typical drug application times for glutamate and IVM
were 10 s and 30 s, respectively. Experiments were conducted at room
temperature (22‡C). IVM was stored frozen as a 10 mM stock solu-
tion in dimethyl sulfoxide for up to 2 weeks. When dissolved into the
perfusion solution, the ¢nal concentration of dimethyl sulfoxide was
no more than 0.1%. Glutamate was also prepared from stock solution
at a concentration of 100 mM (in water).
2.5. Data analysis
The glutamate dose^response relations were measured by applying
a series of glutamate concentrations to each oocyte. Because IVM
responses did not reverse on the time scale of the experiments, only
a single concentration was applied to each oocyte. This response was
normalized to the amplitude of the response to 5 WM IVM in oocytes
(a saturating concentration) of the same batch. Glutamate and IVM
responses to various drug concentrations were ¢tted to the Hill equa-
tion by a non-linear routine, I/Imax = 1/(1+(EC50/[A])n), where I is
agonist-induced current at concentration [A], Imax is the maximum
current, EC50 is the concentration inducing half-maximum response,
and n is the Hill coe⁄cient. Statistical analyses were performed using
unpaired two-population Student’s t-test (as appropriate), with a sig-
ni¢cance level of P6 0.05. All data were presented as meanWS.D.
2.6. Drugs and restriction endonucleases
Glutamate and IVM were purchased from Sigma (St. Louis, MO,
USA); Csp45I was purchased from Promega (Madison, WI, USA);
and the other restriction endonucleases were purchased from New
England Biolabs (Beverly, MA, USA).
3. Results and discussion
3.1. Mutations in the ligand-binding domain and M1 of GluCl L
To eliminate sensitivity to glutamate, we mutated the GluCl
Fig. 1. GluCl sequences in the extracellular ligand-binding domain and M1, compared with other nAChR superfamily members. The C. elegans
GluCl L subunit and K subunit (c GluCl L ; c GluCl K ; GenBank accession numbers U14525 and U14524) were aligned with each other and
the human glycine receptor K1 subunit (h GlyR K1 ; Swiss-Prot P23415), mouse GABA receptor L2 subunit (m GABA L2 ; Swiss-Prot P15432),
human K1 nAChR subunit (h ACh K1 ; Swiss-Prot P02708) and human 5-HT3A subunit (h 5-HT3A ; Swiss-Prot P46098), using MULTALIN
(http://pbil.ibcp.fr/cgi-bin/align_multalin.pl). The ¢rst two Cys residues de¢ne the signature loop common to all nAChR superfamily subunits,
and the second two Cys de¢ne loop C in nAChR. Sixteen highlighted residues on GluCl L were mutated to alanine. At Y182 and Y232 (yellow
residues), tyrosine was also mutated to phenylalanine and tryptophan. Y182 aligns with W149 at nAChR, the site of a cation^Z interaction
with the ligand. T229 and Y232 (yellow residues) align with the crucial nAChR Y190 and Y198, respectively. I269 aligns with I244 in glycine
receptor. Six additional mutations to alanine in loop C were performed, where the residue is not glycine. The other six residues are basic in
GluCl K and GluCl L but not in the other receptors, suggesting they may interact with the acidic group of glutamate. These residues were also
mutated to alanine.
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L subunit, because this subunit is required for glutamate sen-
sitivity [11]. GluCl channels are members of the nicotinic ace-
tylcholine receptor (nAChR) superfamily [10]. Based on struc-
ture^function studies of the glycine receptor [19] and the
crystal structure of the ACh binding protein [14,20], we iden-
ti¢ed 16 residues likely to be involved in the response to glu-
tamate but not to IVM.
Fig. 1 shows the alignment between GluCls and four other
nAChR family members. Residues in red type are completely
conserved; green and blue type denote partial conservation.
The ¢rst two Cys residues de¢ne the ‘signature loop’ common
to all nAChR superfamily subunits, and the second two Cys
de¢ne loop C (nAChR terminology). Y182 in the GluCl L
subunit aligns with W149 at nAChR, the site of a cation^Z
interaction with the ligand [20,21]. T229 and Y232 align with
the crucial nAChR Y190 and Y198, respectively. The glycine
receptor is the closest homolog of GluCls in vertebrates. Rel-
evant site-directed mutagenesis experiments on human glycine
receptors indicate that I244A eliminates glycine sensitivity but
retains IVM sensitivity [19]. I269 at the GluCl L subunit aligns
with this position. These four residues were mutated in the
¢rst round (highlighted in yellow, ¢gure legend, Fig. 1). The
mutations Y182A and Y232A abolished both glutamate and
IVM responses; at these residues, we then performed four
‘milder’ mutations (YCF, W). We have not succeeded in
generating a cDNA for Y232F.
We also generated and analyzed six additional XCA mu-
tations in loop C [22,23], where X is not glycine (highlighted
in green, ¢gure legend, Fig. 1). They are T224A, S225A,
H226A, T227A, N228A and S231A. Red residues in Fig. 1
(R66, K70, R131, K202, K236 and K242) are basic in GluCl
K and GluCl L, but not in the other receptors, suggesting that
they may interact with the acidic group of glutamate; we
mutated these residues to alanine as well.
3.2. Glutamate and IVM responses of WT GluCl receptors
Heteromeric receptors expressed robustly after injections of
25 pg each of cRNA for the GluCl K and L subunits (termed
WT). Response amplitudes were 304W 18 nA (n=33) to 1 mM
glutamate and 675W 26 nA to 1 WM IVM (n=26). Fig. 2 (top
panel) presents an example of WT responses to the agonists.
1 mM glutamate induced a rapid and reversible current (348
nA) while 1 WM IVM induced a slow and irreversible current
(596 nA). The EC50 and the Hill coe⁄cient for WT are
0.48W 0.08 WM and 1.76W 0.31 for IVM and 0.32W 0.05 mM
and 1.69W 0.07 (n=6) for glutamate, respectively.
As expected from previous data [11], responses were much
smaller for equivalent injections of individual cRNAs, which
presumably encoded homomeric receptors. When 25 pg
cRNA of GluCl K or GluCl L was injected, the average re-
sponses to 1 WM IVM or 1 mM glutamate were 24W 6 nA
(n=6) or 79W 8 nA (n=10), respectively, some 10-fold smaller
than the heteromeric responses. Responses were considerably
larger with injection of 250 pg cRNA for the individual sub-
units. Oocytes injected with 250 pg GluCl K cRNA displayed
an IVM dose^response relation with an EC50 of 0.52W 0.06
WM, a Hill coe⁄cient of 2.24 W 0.35, and maximal responses of
1.68W 0.25 WA (n=8); there was little or no response to glu-
tamate. For injections of 250 pg GluCl L cRNA, the responses
Fig. 2. Electrophysiological characterization of WT and three mu-
tated GluCl constructs. Left-hand column, responses to 1 mM glu-
tamate (GLU); right-hand column, responses to 1 WM IVM; the
latter are slower than the glutamate responses and irreversible on
the time scale of the experiments. The top row shows responses in
an oocyte injected with GluCl KL(WT) from C. elegans. Oocytes in-
jected with GluCl KL(I269A) responded well to both glutamate and
IVM. The KL(Y182A) mutant GluCl abolished both glutamate and
IVM responses. The bottom row shows glutamate sensitivity was
abolished but IVM sensitivity was retained in GluCl KL(Y182F).
For each mutant, the two traces shown were obtained from one oo-
cyte. Horizontal line over the traces indicates the application time
of agonists. Xenopus oocytes were injected with 25 pg of both WT
K RNA and WT (or mutated) L RNA.
Table 1
Summary of glutamate and IVM e¡ects on WT and mutant GluCls
GluC1 Glutamate I/IKLðWTÞ IVM I/IKLðWTÞ
K(WT) 0 0.15W 0.04
L(WT) 0.10W 0.02 0
KL(WT) 1 1
KL(Y182A) 0.01W 0.01 0.05W 0.02
KL(T229A) 0.98W 0.17 0.85W 0.29
KL(Y232A) 0.02W 0.01 0.12W 0.05
KL(I269A) 1.36W 0.20 1.29W 0.48
KL(Y182F) 0.16W 0.03 1.06W 0.27
KL(Y182W) 0.14W 0.05 0.32W 0.14
KL(Y232F) N/A N/A
KL(Y232W) 0.14W 0.06 0.29W 0.16
KL(T224A) 0.739 0.352
KL(S225A) 2.23 0.87
KL(H226A) 1.10 0.91
KL(T227A) 0.85 0.73
KL(N228A) 0.93 1.20
KL(S231A) 0.76 1.40
KL(R66A) 0.15 0.45
KL(K70A) 0.48 0.58
KL(R131A) 0.85 0.51
KL(K202A) 1.17 0.55
KL(R236A) 0.02 0.21
KL(K242A) 0.13W 0.06 0.56W 0.15
All mutants were in the L subunit. All values were averaged from at
least ¢ve oocytes. For those mutants examined in more than two
batches of oocytes, data are presented as meanWS.E.M.
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to glutamate displayed an EC50 of 0.24W 0.01 mM, a Hill
coe⁄cient of 1.56 W 0.28 (n=5), and maximal response of
0.90W 0.13 WA (n=15); responses to IVM were small or ab-
sent. The homomeric receptors showed more rapid kinetics
(activation, desensitization and deactivation) than the hetero-
meric responses; we did not study this phenomenon system-
atically.
3.3. Glutamate and IVM responses at mutant receptors
In our ¢rst round of mutagenesis experiments, four con-
structs were tested in oocytes. GluCl KL(T229A) and GluCl
KL(I269A) responded like WT: no signi¢cant di¡erence was
found (Ps 0.05, n=20). Fig. 2 (second row) shows the cur-
rents induced from an oocyte injected with GluCl KL(I269A),
360 nA and 710 nA for glutamate and IVM, respectively. On
the other hand, GluCl KL(Y182A) and GluCl KL(Y232A)
abolished both glutamate and IVM sensitivities (Fig. 2, third
row).
Fifteen additional mutants were examined in the second
round (summarized in Table 1). Mutations to Ala (XCA)
at H226, T227, N228, or S231 did not a¡ect functional ex-
pression (Ps 0.05, n=6); mutations of T224, R131 or K202,
did not a¡ect glutamate response but modestly reduced (two-
to three-fold) the IVM response; and mutations at R66, K70,
R236 and K242 decreased both glutamate and IVM re-
sponses. Mutations (YCW) at Y182 and Y232 also destroyed
both glutamate and IVM sensitivities. GluCl KL(S225A) sig-
ni¢cantly increased the glutamate response to 223% of WT
levels (P6 0.05, n=6). Thus, none of these mutations
achieved the desired results.
3.4. GluCl KL(Y182F) eliminates glutamate responses while
retaining IVM responses
At position Y182 of the GluCl L subunit, three mutations
were constructed (YCA, W, F). The mutants GluCl
KL(Y182A) and GluCl KL(Y182W) abolished the response
of both glutamate and IVM. However, GluCl KL(Y182F)
meets our requirement. An example is shown in Fig. 2 (bot-
tom row). 1 mM glutamate induced a tiny current (V5 nA) in
the oocyte that expressed GluCl KL(Y182F), while 1 WM IVM
induced a current of 827 nA. On average, Y182F, when coex-
pressed with WT GluCl K, reduced the glutamate response to
15.8W 3.4% of WT levels but hardly changed IVM responses
(106W 27%) (n=78) (Fig. 3A). For GluCl KL(Y182F), the
EC50 and Hill coe⁄cient for glutamate is 0.32 W 0.05 mM
and 1.33W 0.25 (n=5), respectively, similar to those of WT
(0.36W 0.04 mM, 1.78W 0.22, n=6) (Fig. 3B), indicating that
the mutant decreases the e⁄cacy of glutamate, but not the
potency.
Tyr-182 aligns with nicotinic receptor residue Trp-149,
which plays an important role in a cation^Z interaction with
the quaternary ammonium moiety of acetylcholine [20,21]. We
conclude that this residue also plays an important role in the
binding or response to both glutamate and IVM in the GluCl
L subunit. The interaction with both ligands is abolished by
mutating the Tyr to Ala or to Trp, but only the interaction
with glutamate is weakened by mutations to Phe. The avail-
able data did not allow a decision about the nature of the
moiety that interacts with Tyr182, or the nature of the inter-
action.
3.5. Functional expression of £uorescent protein-tagged
constructs
Three £uorescent proteins (EGFP, EYFP, ECFP; XFP)
were separately inserted into the M3^M4 loop of the
GluCl K, L and L(Y182F). Firstly, functional expressions of
GluCl K(GFP), GluCl K(YFP), GluCl L(CFP) and GluCl
L(Y182F)(CFP) were expressed as homomers in oocytes and
compared with GluCl K, L and L(Y182F), respectively.
No signi¢cant di¡erence was observed (Ps 0.05, ns 6, data
not shown). Then heteromers with XFP tags in only the
K or L subunit constructs were examined. Data for one of
these constructs are given in Fig. 4A. No signi¢cant dif-
ference was found between GluCl KL(Y182F) and GluCl
Fig. 3. GluCl KL(Y182F) eliminates glutamate sensitivity and retains
IVM sensitivity. A: GluCl KL(Y182F) reduces the glutamate re-
sponse to 15.8% of WT levels but hardly changes IVM responses
(106% of WT values). The values were pooled from 78 oocytes of
six batches, injected with 25 pg to 250 pg of cRNA for each sub-
unit. Error bars are S.E.M. B: Normalized glutamate dose^response
relations for WT and GluCl KL (Y182F). For GluCl KL (Y182F)
(open symbols, dashed line), the curve represents an EC50 of 0.32
mM and an nH of 1.33 (n=5), similar to those of the WT GluCl
KL (closed symbols, solid line) (0.36 mM; 1.78, n=6).
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KL(Y182F)(CFP) (Ps 0.05, n=9). Like GluCl KL(Y182F),
GluCl KL(Y182F)(CFP) abolished the glutamate response to
10.9% of the WT level and almost kept the IVM response
(84.6% of the WT level) (n=7). Finally, doubly XFP-tagged
constructs were expressed to the oocytes. Three di¡erent mo-
lar concentrations of RNA were compared with WT and
XFPs. There is no signi¢cant di¡erence (Ps 0.05, ns 6) be-
tween the responses in oocytes injected with equal molar con-
centrations of WT and XFP RNA (Fig. 4B). The grand aver-
aged data from 30 oocytes showed that XFP hardly changed
the response to both glutamate and IVM (90.8 W 14.2% and
92.0W 7.1% of WT level, respectively) (Fig. 4C). The re-engi-
neered GluCl channel, without glutamate sensitivity but with
a £uorescent tag, may be more useful in GluCl silencing strat-
egies.
3.6. Critique of the GluCl/IVM strategy
Channel-based silencing strategies could mimic either the
endogenous inhibition arising from activation of Kþ channels
(for instance, GABAB receptors coupled to GIRK channels)
or that arising from activation of Cl3 channels (for instance,
GABAA receptors). Most strategies employ Kþ channels [1^
8]. Kþ channels have the advantage that they can be chosen,
or modi¢ed, to display various voltage-dependent and rectify-
ing characteristics. Kþ channels have the disadvantage that
sustained Kþ e¥ux (or Naþ entry) causes apoptosis under
some circumstances [5].
The GluCl/IVM strategy [9] is, to our knowledge, unique
among arti¢cial silencing strategies because it employs Cl3
channels. In most cells, intracellular [Cl3] is on the order of
a few mM; as a result, if GCl rises, intracellular Cl3 is ex-
pected to be driven by the Kþ gradient. Therefore a high Cl3
conductance is expected to clamp the cell near EK, or slightly
hyperpolarized from the normal resting potential, and to
cause only minor changes in intracellular Cl3. One possible
disadvantage to this strategy involves such neurons as dorsal
root ganglia neurons and many immature central nervous
system neurons, whose complement of transporters leads to
a relatively high intracellular Cl3 and therefore a depolarized
ECl. In such a cell, the GluCl/IVM strategy might cause ECl
and EK to approach each other, possibly leading to KCl loss
and to cell shrinkage. It is encouraging that in previous ex-
periments on dorsal root ganglion cells, a heterologously ex-
pressed, continuously active Cl3 conductance did cause a hy-
perpolarizing shift in ECl, but neither shrank nor killed the
cells [24].
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